DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene. It’s the most common inherited neuromuscular disease and affects ...

Patients in the Phase II FORWARD-53 trial (NCT04906460) benefitted from substantial dystrophin expression and the WVE-N531, an exon skipping oligonucleotide, was safe and well tolerated. Off the back ...

Becker muscular dystrophy (BMD) is an X-linked disorder due to in-frame mutations in the DMD gene, leading to a less abundant and truncated dystrophin. BMD is less common and severe than Duchenne ...

Avidity Biosciences is a clinical-stage biotechnology company that develops RNA therapeutics (antibody oligonucleotide ...

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.